MDS 2020 | Challenges hampering clinical utility of fluid biomarkers in Parkinson’s disease

Brit Mollenhauer, MD, University Medical Center Göttingen, Göttingen, Germany, discusses the problems hampering the use of fluid biomarkers in the clinic. Due to an overlap of similar biomarkers, such as ɑ-synuclein, the use of a single value will not provide enough information to make a diagnosis. Additionally, Parkinson’s disease is heterogenous and specific biomarkers would be useful to identify patients vulnerable to particular ailments such as dementia. Currently, the use of fluid biomarkers in the clinic is not appropriate, however developments in technology and greater access to cohorts of patients is promising for research. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).